| PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation P Bai, C Cantó, H Oudart, A Brunyánszki, Y Cen, C Thomas, H Yamamoto, ... Cell metabolism 13 (4), 461-468, 2011 | 890 | 2011 |
| Biology of Poly (ADP-Ribose) Polymerases: The Factotums of Cell Maintenance P Bai Molecular Cell 58 (6), 947-958, 2015 | 458 | 2015 |
| Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction P Pacher, L Liaudet, P Bai, JG Mabley, PM Kaminski, L Virág, A Deb, ... Circulation 107 (6), 896-904, 2003 | 356 | 2003 |
| The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease P Bai, C Cantó Cell Metabolism 16 (3), 290-295, 2012 | 336 | 2012 |
| Parp-2 regulates sirt1 expression and whole-body energy expenditure P Bai, C Canto, A Brunyánszki, A Huber, M Szántó, Y Cen, H Yamamoto, ... Cell metabolism 13 (4), 450-460, 2011 | 300 | 2011 |
| PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development A Huber, P Bai, JM De Murcia, G De Murcia DNA repair 3 (8-9), 1103-1108, 2004 | 287 | 2004 |
| Crosstalk between poly (ADP-ribose) polymerase and sirtuin enzymes C Cantó, AA Sauve, P Bai Molecular aspects of medicine 34 (6), 1168-1201, 2013 | 271 | 2013 |
| Activation of poly (ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure P Pacher, L Liaudet, P Bai, L Virag, JG Mabley, G Hasko, C Szabo Journal of Pharmacology and Experimental Therapeutics 300 (3), 862-867, 2002 | 237 | 2002 |
| ADP‐ribosyltransferases, an update on function and nomenclature B Lüscher, I Ahel, M Altmeyer, A Ashworth, P Bai, P Chang, M Cohen, ... The FEBS journal 289 (23), 7399-7410, 2022 | 217 | 2022 |
| Microbiome—Microbial Metabolome—Cancer Cell Interactions in Breast Cancer—Familiar, but Unexplored E Mikó, T Kovács, É Sebő, J Tóth, T Csonka, G Ujlaki, A Sipos, J Szabó, ... Cells 8 (4), 293, 2019 | 169 | 2019 |
| Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness E Mikó, A Vida, T Kovács, G Ujlaki, G Trencsényi, J Márton, Z Sári, ... Biochimica et Biophysica Acta (BBA)-Bioenergetics 1859 (9), 958-974, 2018 | 162 | 2018 |
| PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis P Mukhopadhyay, B Horváth, M Rajesh, ZV Varga, K Gariani, D Ryu, ... Journal of hepatology 66 (3), 589-600, 2017 | 158 | 2017 |
| Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors T Kovács, E Mikó, A Vida, É Sebő, J Toth, T Csonka, A Boratkó, G Ujlaki, ... Scientific Reports 9 (1), 1300, 2019 | 156 | 2019 |
| Targeting the gut‐skin axis–probiotics as new tools for skin disorder management? PB M Szántó, A Dózsa, D Antal, K Szabó, L Kemény Experimental Dermatology, doi: 10.1111/exd.14016, 2019 | 148* | 2019 |
| Gallotannin inhibits the expression of chemokines and inflammatory cytokines in A549 cells K Erdelyi, A Kiss, E Bakondi, P Bai, C Szabo, P Gergely, F Erdödi, L Virag Molecular pharmacology 68 (3), 895-904, 2005 | 132 | 2005 |
| Dual role of poly (ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells K Erdélyi, P Bai, I Kovács, É Szabó, G Mocsár, A Kakuk, C Szabó, ... The FASEB Journal 23 (10), 3553-3563, 2009 | 131 | 2009 |
| Peroxisome proliferator-activated receptor (PPAR)-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid X … P Bai, SM Houten, A Huber, V Schreiber, M Watanabe, B Kiss, ... Journal of Biological Chemistry 282 (52), 37738-37746, 2007 | 131* | 2007 |
| The role of bile acids in carcinogenesis T Režen, D Rozman, T Kovács, P Kovács, A Sipos, P Bai, E Mikó Cellular and Molecular Life Sciences 79 (5), 243, 2022 | 128 | 2022 |
| Role of poly (ADP-ribose) polymerases in the regulation of inflammatory processes P Bai, L Virág FEBS letters 586 (21), 3771-3777, 2012 | 125 | 2012 |
| A2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue inflammation via maintaining alternative macrophage activation B Csóka, B Koscsó, G Törő, E Kókai, L Virág, ZH Németh, P Pacher, P Bai, ... Diabetes 63 (3), 850-866, 2014 | 124 | 2014 |
Laszlo ViragProfessor of Medical Chemistry, University of Debrecen, Faculty of Medicine, HungaryVerified email at med.unideb.hu